The inflammatory reaction induced by formalin in the rat paw

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 359, Issue 3, 1999, Pages 220-227

  Damas, Jacques ^a   Liégeois, Jean François ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bradykinin; Formalin; NS 398; Oedema; Substance P

Indexed keywords

AUTACOID; BRADYKININ; FORMALDEHYDE; HISTAMINE; NEUROPEPTIDE; PROSTANOID; SEROTONIN; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; EDEMA; INFLAMMATION; MALE; NEUROGENIC INFLAMMATION; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN; PAIN RECEPTOR; RAT;

EID: 0033042980     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005345     Document Type: Article

References (45)

1. Abbott FV, Franklin KBJ, Westbrook RF (1995) The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain 60:91-102
2. Andrews PV, Helme RD, Thomas KL (1989) NK-1 receptor mediation of neurogenic plasma extravasation in rat skin. Br J Pharmacol 97:1232-1238
3. A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50:291-313
4. Beresford IJM, Birch PJ (1992) Antinociceptive activity of the bradykinin antagonist HOE-140 in rat and mouse. Br J Pharmacol 105:135P
5. 2 bradykinin receptor knockout mice. Br J Pharmacol 117:245P
6. Buritova J, Chapman V, Honoré P, Besson JM (1996) Seclective cyclooxygenase-2 inhibition reduces carrageenan oedema and associated spinal c-Fos expression in the rat. Brain Res 715:217-220
7. Chapman V, Dickenson AH (1992) The spinal and peripheral roles of bradykinin and prostaglandins in nociceptive processing in the rat. Eur J Pharmacol 219:427-433
8. Chapman V, Buritova J, Honoré P, Besson JM (1995) 7-nitroindazole, a selective inhibitor of neuronal nitric oxide synthase, reduces formalin evoked c-Fos expression in dorsal horn neurons of the rat spinal cord. Brain Res 697:258-261
9. 2 kinin receptors in formalin-induced nociceptive response in the mouse. Br J Pharmacol 110:193-198
10. 2 bradykinin receptor antagonist NPC 18688 in mice. Br J Pharmacol 117:552-558
11. Damas J (1996) The Brown Norway rats and the kinin system. Peptides 17:859-872
12. Damas J, Remade-Volon G (1992) Influence of a long-acting bradykinin antagonist, HOE 140, on some acute inflammatory reactions in the rat. Eur J Pharmacol 211:81-86
13. Damas J, Bourdon V, Souza Pinto JC (1995) The myostimulating effect of tissue kallikrein on rat uterus. Naunyn Schmiedebergs Arch Pharmacol 351:535-541
14. Damas J, Bourdon V, Liégeois JF, Simmons WH (1996a) Influence of several peptidase inhibitors on the pro-inflammatory effects of substance P, capsaicin and collagenase. Naunyn Schmiedebergs Arch Pharmacol 354:662-669
15. Damas J, Liégeois JF, Simmons WH (1996b) Potentiation of the proinflammatory effects of bradykinin by inhibition of angiotensin-converting enzyme and aminopeptidase P in rat paws. Naunyn Schmiedebergs Arch Pharmacol 354:670-676
16. 2 receptors. Br J Pharmacol 118:2206-2212
17. 2 receptor antagonist. Eur J Pharmacol 316:227-286
18. Delay-Goyet P, Satoh H, Lundberg JM (1992) Relative involvement of substance P and CGRP mechanisms in antidromic vasodilation in the rat skin. Acta Physiol Scand 146:537-538
19. Dray A, Perkins M (1993) Bradykinin and inflammatory pain. Trends Neurosci 16:99-104
20. Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel JF, Blanchard JC, Laduron P (1991) Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA 88:10208-10212
21. Holzer P (1991) Capsaicin: cell targets, mechanisms of actions and selectivity for thin sensory neurons. Pharmacol Rev 43:143-201
22. Hong Y, Abbott FV (1995) Peripheral opioid modulation of pain and inflammation in the formalin test. Eur J Pharmacol 277:21-28
23. Hunskaar S, Hole K. (1987) The formalin test in mice: dissociation between infflammatory and non-inflammatory pain. Pain 30:103-114
24. Ito K, Sakamoto T, Hayashi Y, Morishita M, Shibata E, Sakai K, Takeuchi Y, Torii S (1996) Role of tachykinin and bradykinin receptors and mast cells in gaseous formaldehyde-induced airway microvascular leakage in rats. Eur J Pharmacol 307:291-298
25. Lembeck F, Donnerer J (1985) Opioid control of the function of primary afferent substance P fibres. Eur J Pharmacol 114:241-249
26. Lembeck F, Holzer P (1979) Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310:175-183
27. 5] enkephalinamide. Eur J Pharmacol 85:171-176
28. Lembeck F, Donnerer J, Tsushiya M, Nagahisa A (1992) The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol 105:527-530
29. Manning DC, Raja SN, Meyer RA, Campbell JN (1991) Pain and hyperalgesia after intradermal injections of bradykinin in humans. Clin Pharmacol Ther 50:721-729
30. Matsumoto H, Naraba H, Ueno A, Fujiyoshi T, Murakami M, Kudo I, Oh-ishi S (1998) Induction of cyclooxygenase-2 causes an enhancement of writhing response in mice. Eur J Pharmacol 352:47-52
31. Mentlein R, Roos T (1996) Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides 17:709-720
32. G-nitro arginine methyl ester exhibits antinociceptive activity in the mouse. Br J Pharmacol 102:198-202
33. 1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically. Br J Pharmacol 109:259-264
34. Proud D, Kaplan AP (1988) Kinin formation: mechanisms and role in inflammation disorders. Ann Rev Immunol 6:49-83
35. Rupniak NMJ, Boyce S, Williams AR, Cook G, Longmore J, Seabrook GR, Caeser M, Iversen SD, Hill RG (1993) Antinociceptive of NK1 receptor antagonists: non-specific effects of racemic RP67580. Br J Pharmacol 110:1607-1613
36. 2 receptor antagonists: a comparison to other classes of antinociceptive agent. Pain 61:325-343
37. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013-12017
38. Shibata M, Ohkubo T, Takahashi H, Inoki R (1989) Modified formalin test: characteristic biphasic pain response. Pain 38:347-352
39. Sluka KA, Willis WD, Westlund KN (1993) Joint inflammation and hyperalgesia are reduced by spinal bicuculline. Neuroreport 5:109-112
40. 1 receptor antagonist, SR140333, but not by a bradykinin antagonist, HOE 140, in rat skin. Br J Pharmacol 119:203P
41. Trautschold I (1970) Assay methods in the kinin system. In: Erdös EG (ed) Bradykinin, kallidin, kallikrein. Handbook of experimental pharmacology, vol 25. Springer, Berlin Heidelberg New York, pp 52-81
42. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232-235
43. Wang LH, Ahmad S, Benter IF, Chow A, Mizutani S, Ward PE (1991) Differential processing of substance P and neurokinin A by plasma dipeptidyl-(amino)peptidase IV, aminopeptidas M and angiotensin converting-enzyme. Peptides 12:1357-1364
44. 2+ concentration in bovine pulmonary artery endothelial cells. Eur J Pharmacol 342:359-366
45. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Agnastopoulos H, Henke S, Breipohl G, König W, Knolle J, Schölkens BA (1991) HOE 140, a new potent and long-acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 102:774-777